Vertex Pharmaceuticals’ (VRTX) Outperform Rating Reiterated at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...
Hosted on MSN11mon
Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX ... Adjusted operating expense was $1.0 billion in the quarter, up 15% year over year. Adjusted R&D expenses ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
bovnews11d
Vertex Pharmaceuticals Inc (VRTX) Stock’s 0.04% Increase This Year: What’s the Story?
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...
Seeking Alpha17d
McKesson, Vertex Pharmaceuticals among top healthcare Quant picks before Q4 earnings
Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given its dominance in the cystic fibrosis treatment category and diversified pipeline, making a compelling case ...